


What is claimed is:

1. A compound of Formula I or a pharmaceutically acceptable salt thereof



wherein

R is C<sub>1-4</sub> alkyl, CF<sub>3</sub> or hydroxymethyl;


R<sup>1</sup> and R<sup>2</sup> are each independently hydrogen, C<sub>1-4</sub> alkyl, halogen or morpholin-4-yl;

R<sup>4</sup> is selected from the group consisting of optionally substituted morpholin-4-yl, pyridinyl, pyrimidinyl, piperazinyl, and pyrazinyl, in which said substituent is independently selected from the group consisting of C<sub>1-4</sub>alkyl, dimethylamino, hydroxymethyl, chloro and fluoro;

R<sup>5</sup> is hydrogen or fluoro; or R<sup>4</sup> and R<sup>5</sup> taken together are -CH=CH-CH=CH- or -CH<sub>2</sub>CH<sub>2</sub>O-; and

R<sup>3</sup>, R<sup>6</sup> and R<sup>7</sup> are each independently selected from hydrogen or fluoro.

2. The compound of claim 1 having the Formula Ic or a pharmaceutically acceptable salt thereof



wherein

R is methyl or hydroxymethyl;

R<sup>1</sup> and R<sup>2</sup> are each independently hydrogen, C<sub>1-4</sub> alkyl, halogen or morpholin-4-yl;

R<sup>4</sup> is selected from the group consisting of optionally substituted morpholin-4-yl, pyridinyl, pyrimidinyl, piperazinyl, and pyrazinyl, in which said  
5 substituent is independently selected from the group consisting of C<sub>1-4</sub>alkyl, dimethylamino, hydroxymethyl, chloro and fluoro;

R<sup>5</sup> is hydrogen or fluoro; or R<sup>4</sup> and R<sup>5</sup> taken together are -CH=CH-CH=CH- or -CH<sub>2</sub>CH<sub>2</sub>O-; and

R<sup>3</sup>, R<sup>6</sup> and R<sup>7</sup> are each independently selected from hydrogen or fluoro.

10

3. The compound of claim 1 selected from the group consisting of:

2-(2-fluoro-phenyl)-cyclopropanecarboxylic acid [1-(2,3-dihydro-benzofuran-5-yl)-ethyl]-amide;

15 2-(3-fluoro-phenyl)-cyclopropanecarboxylic acid [1-(2,3-dihydro-benzofuran-5-yl)-ethyl]-amide;

2-(4-fluoro-phenyl)-cyclopropanecarboxylic acid [1-(2,3-dihydro-benzofuran-5-yl)-ethyl]-amide ;

2-(2-fluoro-phenyl)-cyclopropanecarboxylic acid (2-hydroxy-1-naphthalen-2-yl-ethyl)-amide;

20 2-(3-fluoro-phenyl)-cyclopropanecarboxylic acid (2-hydroxy-1-naphthalen-2-yl-ethyl)-amide;

2-(4-fluoro-phenyl)-cyclopropanecarboxylic acid (2-hydroxy-1-naphthalen-2-yl-ethyl)-amide;

25 2-(2,5-difluoro-phenyl)-cyclopropanecarboxylic acid (2-hydroxy-1-naphthalen-2-yl-ethyl)-amide;

2-(2-fluoro-phenyl)-cyclopropanecarboxylic acid [1-(4-fluoro-3-morpholin-4-yl-phenyl)-2-hydroxy-ethyl]-amide;

2-(3-fluoro-phenyl)-cyclopropanecarboxylic acid [1-(4-fluoro-3-morpholin-4-yl-phenyl)-2-hydroxy-ethyl]-amide;

30 2-(4-fluoro-phenyl)-cyclopropanecarboxylic acid [1-(4-fluoro-3-morpholin-4-yl-phenyl)-2-hydroxy-ethyl]-amide;

- 2-(2,5-difluoro-phenyl)-cyclopropanecarboxylic acid [1-(4-fluoro-3-morpholin-4-yl-phenyl)-2-hydroxy-ethyl]-amide;  
2-(4-fluoro-phenyl)-cyclopropanecarboxylic acid (1-naphthalen-2-yl-ethyl)-amide;
- 5 2-(2,5-difluoro-phenyl)-cyclopropanecarboxylic acid (1-naphthalen-2-yl-ethyl)-amide;  
2-(4-fluoro-phenyl)-cyclopropanecarboxylic acid {1-[3-(3-dimethylamino-pyrrolidin-1-yl)-phenyl]-ethyl}-amide;  
2-(2,5-difluoro-phenyl)-cyclopropanecarboxylic acid {1-[3-(3-dimethylamino-pyrrolidin-1-yl)-phenyl]-ethyl}-amide;
- 10 2-(3-fluoro-phenyl)-cyclopropanecarboxylic acid [1-(3-pyridin-3-yl-phenyl)-ethyl]-amide;  
2-(2,5-difluoro-phenyl)-cyclopropanecarboxylic acid [1-(3-pyridin-3-yl-phenyl)-ethyl]-amide;
- 15 (S)-2-phenyl-cyclopropanecarboxylic acid [1-(3-pyridin-3-yl-phenyl)-ethyl]-amide;  
(S)-2-(3-fluoro-phenyl)-cyclopropanecarboxylic acid {1-[3-(6-fluoro-pyridin-3-yl)-phenyl]-ethyl}-amide;  
(S)-2-phenyl-cyclopropanecarboxylic acid {1-[3-(2-fluoro-pyridin-3-yl)-phenyl]-ethyl}-amide; and
- 20 (S)-2-(2-fluoro-phenyl)-cyclopropanecarboxylic acid {1-[3-(2-fluoro-pyridin-3-yl)-phenyl]-ethyl}-amide;  
or a pharmaceutically acceptable salt thereof.
- 25 4. A pharmaceutical composition for the treatment of disorders responsive to opening of KCNQ potassium channels comprising a therapeutically effective amount of the compound of claim 1 in association with a pharmaceutically acceptable carrier, adjuvant or diluent.
- 30 5. A method for the treatment of disorders responsive to opening of the KCNQ potassium channels in a mammal in need thereof, which comprises

administering to said mammal a therapeutically effective amount of the compound of claim 1.

6. The method of claims 5 wherein said disorders are acute and chronic pain,  
5 migraine, neuropathic pain, bipolar disorders, convulsions, mania, epilepsy, anxiety, depression and neurodegenerative disorders.
7. The method of claim 6 wherein said disorder is migraine.
- 10 8. The method of claim 6 wherein said disorder is neuropathic pain.